Last reviewed 2026-04-23 · How we verify

Teneligliptin + Sulfonylurea

Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while the sulfonylurea component stimulates pancreatic beta cells to release insulin.

Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while the sulfonylurea component stimulates pancreatic beta cells to release insulin. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

This is a fixed-dose combination where teneligliptin, a DPP-4 inhibitor, prolongs the action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance glucose-dependent insulin secretion. The sulfonylurea component provides additional insulin secretion through direct beta-cell stimulation via ATP-sensitive potassium channel closure, offering complementary mechanisms for glycemic control in type 2 diabetes.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Hypoglycemia
• Upper respiratory tract infection
• Nasopharyngitis
• Headache
• Weight gain

Key clinical trials

• Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes (PHASE3)
• Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Teneligliptin + Sulfonylurea CI brief — competitive landscape report
• Teneligliptin + Sulfonylurea updates RSS · CI watch RSS
• Tanabe Pharma Corporation portfolio CI